Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.
Nielsen SN, Eriksson F, Rosthoej S, Andersen MK, Forestier E, Hasle H, Hjalgrim LL, Aasberg A, Abrahamsson J, Heyman M, Jónsson ÓG, Pruunsild K, Vaitkeviciené GE, Vettenranta K, Schmiegelow K. Nielsen SN, et al. Among authors: vettenranta k. Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26518. Epub 2017 May 13. Pediatr Blood Cancer. 2017. PMID: 28500740
Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R; Nordic Society for Paediatric Haematology and Oncology. Schmiegelow K, et al. Among authors: vettenranta k. Blood. 2009 Jun 11;113(24):6077-84. doi: 10.1182/blood-2008-11-187880. Epub 2009 Feb 17. Blood. 2009. PMID: 19224761 Free PMC article.
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. Among authors: vettenranta k. J Pediatr Hematol Oncol. 2009 Jun;31(6):385-92. doi: 10.1097/MPH.0b013e3181a6e171. J Pediatr Hematol Oncol. 2009. PMID: 19648786 Clinical Trial.
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Toft N, Birgens H, Abrahamsson J, Bernell P, Griškevičius L, Hallböök H, Heyman M, Holm MS, Hulegårdh E, Klausen TW, Marquart HV, Jónsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Åsberg A, Schmiegelow K. Toft N, et al. Among authors: vettenranta k. Eur J Haematol. 2013 May;90(5):404-12. doi: 10.1111/ejh.12097. Epub 2013 Apr 2. Eur J Haematol. 2013. PMID: 23461707
Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, Klausen TW, Jónsson ÓG, Palk K, Pruunsild K, Quist-Paulsen P, Vaitkeviciene G, Vettenranta K, Asberg A, Helt LR, Frandsen T, Schmiegelow K. Toft N, et al. Among authors: vettenranta k. Eur J Haematol. 2016 Feb;96(2):160-9. doi: 10.1111/ejh.12562. Epub 2015 Apr 24. Eur J Haematol. 2016. PMID: 25867866
Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials.
Tulstrup M, Larsen HB, Castor A, Rossel P, Grell K, Heyman M, Abrahamsson J, Söderhäll S, Åsberg A, Jonsson OG, Vettenranta K, Frandsen TL, Albertsen BK, Schmiegelow K; Nordic Society of Paediatric Haematology, and Oncology (NOPHO). Tulstrup M, et al. Among authors: vettenranta k. Pediatr Blood Cancer. 2016 May;63(5):865-71. doi: 10.1002/pbc.25887. Epub 2015 Dec 31. Pediatr Blood Cancer. 2016. PMID: 26717887 Clinical Trial.
Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
Schmiegelow K, Nersting J, Nielsen SN, Heyman M, Wesenberg F, Kristinsson J, Vettenranta K, Schrøeder H, Weinshilboum R, Jensen KL, Grell K, Rosthoej S. Schmiegelow K, et al. Among authors: vettenranta k. Pediatr Blood Cancer. 2016 Dec;63(12):2104-2111. doi: 10.1002/pbc.26139. Epub 2016 Jul 22. Pediatr Blood Cancer. 2016. PMID: 27447547
Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial.
Tulstrup M, Frandsen TL, Abrahamsson J, Lund B, Vettenranta K, Jonsson OG, Marquart HVH, Albertsen BK, Heyman M, Schmiegelow K. Tulstrup M, et al. Among authors: vettenranta k. Eur J Haematol. 2018 Jan;100(1):53-60. doi: 10.1111/ejh.12979. Epub 2017 Nov 9. Eur J Haematol. 2018. PMID: 28983968 Clinical Trial.
182 results